Is Ripretinib on the market?

Ripretinib was approved for medical use by the U.S. Food and Drug Administration (FDA) in May 2020, in Australia in July 2020, and in the European Union in November 2021. Repetinib is an oral kinase inhibitor used to treat patients with gastrointestinal stromal tumor (GIST) who have not responded adequately to other kinase inhibitors such as sunitinib (sunitinib) and imatinib (imatinib).

Ripetinib also known asQinlock, produced by Deciphera Pharmaceuticals, is the first drug approved as a fourth-line therapy for special conditions that have been previously treated with at least 3 other kinase inhibitors. The most common side effects include hair loss, fatigue, nausea, abdominal pain, constipation, myalgia, diarrhea, decreased appetite, palmar-plantar dysesthesia syndrome (skin reactions on the palms and soles of the feet), and vomiting.

The original drug of Ripetinib has been marketed in China and has been approved by the National Medical Insurance Bureau to enter the scope of Class B medical insurance, but it is limited to patients who meet the indications. The price of each box of 50mg*30 tablets may be around 30,000 yuan. The expensive price may increase the pressure on families with heavy financial burdens. The US version of Ripetinib Specifications50mg*90 tablets sold overseas may be priced around RMB 77,000 per box (the price may fluctuate due to exchange rates). The ingredients of foreign original drugs are basically the same as those of domestic original drugs. Currently, there is no generic drug of Ripetinib produced and marketed overseas. For specific prices and drug information, please consult Yaode’s medical consultant.